Umberto M Battisti1, Ramsey Sitta2, Alan Harris2, Farhana Sakloth3, Donna Walther4, Iwona Ruchala2, S Stevens Negus3, Michael H Baumann4, Richard A Glennon1, Jose M Eltit2. 1. Department of Medicinal Chemistry, School of Pharmacy, Box 980540 , Virginia Commonwealth University , Richmond , Virginia 23298 , United States. 2. Department of Physiology and Biophysics, School of Medicine , Virginia Commonwealth University , Richmond , Virginia 23298 United States. 3. Department of Pharmacology and Toxicology, School of Medicine , Virginia Commonwealth University , Richmond , Virginia 23298 , United States. 4. Designer Drug Research Unit, Intramural Research Program , National Institute on Drug Abuse, National Institutes of Health , Baltimore , Maryland 21224 , United States.
Abstract
4-Methylamphetamine (4-MA) is an emerging drug of abuse that acts as a substrate at plasma membrane transporters for dopamine (DAT), norepinephrine (NET), and serotonin (SERT), thereby causing nonexocytotic release of monoamine transmitters via reverse transport. Prior studies by us showed that increasing the N-alkyl chain length of N-substituted 4-MA analogues converts 4-MA from a transportable substrate (i.e., releaser) at DAT and NET to a nontransported blocker at these sites. Here, we studied the effects of the individual optical isomers of N-methyl-, N-ethyl-, and N- n-propyl 4-MA on monoamine transporters and abuse-related behavior in rats because action/function might be related to stereochemistry. Uptake inhibition and release assays were conducted in rat brain synaptosomes whereas electrophysiological assessments of drug-transporter interactions were examined using cell-based biosensors. Intracranial-self-stimulation in rats was employed to assess abuse potential in vivo. The experimental evidence demonstrates that S(+) N-methyl 4-MA is a potent and efficacious releaser at DAT, NET, and SERT with the highest abuse potential among the test drugs, whereas R(-) N-methyl 4-MA is a less potent releaser with reduced abuse potential. The S(+)ethyl analogue has decreased efficacy as a releaser at DAT but retains full release activity at NET and SERT with a reduction in abuse-related effects; the R(-)ethyl analogue has a similar profile but is less potent. S(+) N-Propyl 4-MA is a nontransported blocker at DAT and NET but an efficacious releaser at SERT, whereas the R enantiomer is almost inactive. In conclusion, the S enantiomers of the N-alkyl 4-MA analogues are most potent. Lengthening the N-alkyl chain converts compounds from potent nonselective releasers showing abuse-related effects to more selective SERT releasers with no apparent abuse potential.
4-Methylamphetamine (n class="Chemical">4-MA) is an emerging drug of abuse that acts as a substrate at plasma membrane transporters for dopamine (DAT), norepinephrine (NET), and serotonin (SERT), thereby causing nonexocytotic release of monoamine transmitters via reverse transport. Prior studies by us showed that increasing the N-alkyl chain length of N-substituted 4-MA analogues converts 4-MA from a transportable substrate (i.e., releaser) at DAT and NET to a nontransported blocker at these sites. Here, we studied the effects of the individual optical isomers of N-methyl-, N-ethyl-, and N- n-propyl 4-MA on monoamine transporters and abuse-related behavior in rats because action/function might be related to stereochemistry. Uptake inhibition and release assays were conducted in rat brain synaptosomes whereas electrophysiological assessments of drug-transporter interactions were examined using cell-based biosensors. Intracranial-self-stimulation in rats was employed to assess abuse potential in vivo. The experimental evidence demonstrates that S(+) N-methyl 4-MA is a potent and efficacious releaser at DAT, NET, and SERT with the highest abuse potential among the test drugs, whereas R(-) N-methyl 4-MA is a less potent releaser with reduced abuse potential. The S(+)ethyl analogue has decreased efficacy as a releaser at DAT but retains full release activity at NET and SERT with a reduction in abuse-related effects; the R(-)ethyl analogue has a similar profile but is less potent. S(+) N-Propyl 4-MA is a nontransported blocker at DAT and NET but an efficacious releaser at SERT, whereas the R enantiomer is almost inactive. In conclusion, the S enantiomers of the N-alkyl 4-MA analogues are most potent. Lengthening the N-alkyl chain converts compounds from potent nonselective releasers showing abuse-related effects to more selective SERT releasers with no apparent abuse potential.
Authors: Iwona Ruchala; Vanessa Cabra; Ernesto Solis; Richard A Glennon; Louis J De Felice; Jose M Eltit Journal: Cell Calcium Date: 2014-04-27 Impact factor: 6.817
Authors: Ryan A Gregg; Michael H Baumann; John S Partilla; Julie S Bonano; Alexandre Vouga; Christopher S Tallarida; Venkata Velvadapu; Garry R Smith; M Melissa Peet; Allen B Reitz; S Stevens Negus; Scott M Rawls Journal: Br J Pharmacol Date: 2014-12-15 Impact factor: 8.739
Authors: Ernesto Solis; John S Partilla; Farhana Sakloth; Iwona Ruchala; Kathryn L Schwienteck; Louis J De Felice; Jose M Eltit; Richard A Glennon; S Stevens Negus; Michael H Baumann Journal: Neuropsychopharmacology Date: 2017-05-22 Impact factor: 7.853
Authors: L D Simmler; T A Buser; M Donzelli; Y Schramm; L-H Dieu; J Huwyler; S Chaboz; M C Hoener; M E Liechti Journal: Br J Pharmacol Date: 2013-01 Impact factor: 8.739
Authors: Megan J Moerke; Subramaniam Ananthan; Matthew L Banks; Jose M Eltit; Kelen C Freitas; Amy R Johnson; Surendra K Saini; Tyler W E Steele; S Stevens Negus Journal: J Pharmacol Exp Ther Date: 2018-08-27 Impact factor: 4.030
Authors: Tyler W E Steele; Zachary Spires; Charles B Jones; Richard A Glennon; Małgorzata Dukat; Jose M Eltit Journal: Neuropharmacology Date: 2021-10-04 Impact factor: 5.250
Authors: Iwona Ruchala; Umberto M Battisti; Vy T Nguyen; Rita Yu-Tzu Chen; Richard A Glennon; Jose M Eltit Journal: Toxicol Appl Pharmacol Date: 2021-03-27 Impact factor: 4.219